merck...

interesting new shopping list for merck to add to isentress!

We are particularly interested in compounds that have a large market potential for unmet medical needs.
Late-stage clinical compounds with proven therapeutic value (phase IIb or beyond) are of interest in any therapeutic area.

...

Phase IIb or later in development:
• Nucleoside reverse transcriptase inhibitors with differentiated resistance profile to existing agents, QD dosing

...

Phase I or later in development:
• Integrase inhibitors with new MOA or novel structural
scaffold with QD dosing; would consider BID dosing with
differentiated resistance profile

...

Preclinical:
• Compounds with compelling preclinical documentation to
treat bacterial disease, including efficacy in validated animal
models of infection and preliminary toxicology data
Phase I or later:
• Gram-negative or gram-positive agents (narrow and
broad spectrum) that cover problematic pathogens with
either intrinsic or acquired resistance to existing agents,
particularly MRSA, Pseudomonas, and Acinetobacter
(IV with oral step-down a plus)
• Novel approaches to C. difficile that address the
recrusdescence rate
• Combinations that address bacterial resistance

http://www.merck.com/licensing/pdf/aoi_may_2009.pdf